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OBJECTIVE: To evaluate the clinical, cost, and value implica-
tions of using epidermal growth factor receptor (EGFR) testing
to guide treatment of refractory non-small cell lung cancer
(NSCLC) patients compared to standard empirical treatments.
METHODS: We developed a decision analytic model to evaluate
the cost-utility of using EGFR protein expression or EGFR gene
copy number testing compared to standard treatments (erlotinib,
docetaxel, or pemetrexed) in refractory advanced NSCLC
patients using the societal perspective and a two-year time frame.
Survival, cost, and utility inputs were obtained from publicly
available sources. We evaluated the uncertainty in the model
using one-way and probabilistic sensitivity analyses as well as an
expected value of perfect information (EVPI) analysis. RESULTS:
In the base case, the lifetime QALY estimates ranged from 0.431
for docetaxel to 0.502 for gene copy number testing with pem-
etrexed for those testing negative (GC/PEM). Lifetime cost
estimates ranged from $57,200 for erlotinib to $71,800 for pem-
etrexed. After removing dominated interventions, erlotinib domi-
nated docetaxel, gene copy number testing with docetaxel for
those testing negative (GC/DOC) had an ICER of $162,018/
QALY versus erlotinib, and GC/PEM had an ICER of
$2,487,867/QALY versus GC/DOC. The model results were
most sensitive to overall survival, progression-free survival,
health state utilities, and drug acquisition cost inputs. In the
probabilistic sensitivity analyses, GC/DOC had a 14% probabil-
ity of decreasing costs and an 83% probability of increasing
QALYs versus Erlotinib. The discounted EVPI at a $100,000/
QALY threshold in the US population over a 5-year time frame
was $38.1 million dollars and represents the upper limit value of
additional information. CONCLUSION: The results of our
analysis suggest treatment of refractory NSCLC using a pharma-
cogenomic test based on gene copy number has the potential to
improve average QALYs at considerable additional costs. The
large EVPI suggests that additional research in this area is likely
warranted.
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OBJECTIVE: A multicenter phase III randomized trial showed
that six cycles of TAC (Taxotere® plus doxorubicin and cyclo-
phosphamide) showed improved disease free survival (DFS) and
overall survival (OS) over six cycles of FAC (ﬂuorouracil plus
doxorubicin and cyclophosphamide) for adjuvant chemotherapy
of patients with operable node-positive unilateral breast cancer.
The objective of the economic analysis was to determine the
cost-effectiveness of TAC compared to FAC following primary
surgery for breast cancer in women with operable, axillary-
lymph-node-positive breast cancer from a Canadian provincial
government payer perspective. METHODS: The time horizon
chosen for the model is a lifetime horizon. A Markov model was
constructed looking at two time phases: ﬁrst ﬁve years including
treatment and long term follow-up. Clinical events included clini-
cal response based on DFS and OS, as well as rates of febrile
neutropenia, stomatitis, diarrhea and infections. Costs (2006
CAN$) were based on published sources and included chemo-
therapy drug acquisition costs, chemotherapy administration
costs, relapse costs and follow-up costs, management of adverse
events costs and costs for G-CSF prophylaxis. Health utilities
were obtained from published sources and applied to each health
state used in the model. A 5% discount rate was used on costs
and outcomes. RESULTS: The incremental cost per life year (LY)
gained for TAC compared to FAC was $9248/LY gained. The
incremental cost per quality-adjusted life year (QALY) gained for
TAC compared to FAC was $9150/QALY gained. The model was
robust to changes in input variables (e.g., febrile neutropenia
rate, utility). When G-CSF and antibiotics were given prophylac-
tically before every cycle, the incremental ratio changed to
$15,538/LY gained and $15,374/QALY. CONCLUSION: TAC
offers improved response at a higher cost than FAC. The cost
effectiveness ratios are low, indicating good economic value in
the adjuvant setting of node positive breast cancer patients.
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OBJECTIVE: Neutropenia is a major adverse event often asso-
ciated with chemotherapy administration. The purpose of this
study was to evaluate costs for chemotherapy-related neutrope-
nia (N) and febrile neutropenia (FN) in an elderly population
with advanced NSCLC. METHODS: Study patients included
those aged 65 years and older with a diagnosis of Stage IIIB/IV
NSCLC in the SEER cancer registry from 1998 through 2002.
Neutropenia patients were followed in the SEER-Medicare data-
base to evaluate the costs associated with N and FN. Neutro-
penia was identiﬁed by the presence of a primary or secondary
ICD-9-CM 288.x diagnostic code during a period of chemo-
therapy treatment. FN was deﬁned by an inpatient hospitaliza-
tion for neutropenia or antibiotic administration following the
initial neutropenia diagnosis. All Medicare payments were
summed for two main types of cost measures: neutropenia-
related costs and costs unrelated to neutropenia. Costs were
classiﬁed using ICD-9-CM diagnosis and procedure codes
appearing on the claims, with conﬁdence intervals for all cost
measures estimated by using non-parametric bootstrapping tech-
niques. RESULTS: Among elderly patients treated ﬁrst-line for
advanced NSCLC, 5138 were identiﬁed who met inclusion cri-
teria. Nearly one-quarter (N = 1228) developed N or FN while
on ﬁrst-line chemotherapy. Mean ﬁrst-line neutropenia-related
costs for FN were $11,661 (95% CI: 10,493–13,098) compared
to $2817 (95% CI: 2522–3124) for N, with length of follow-up
of 134 and 165 days respectively. Costs related to neutropenia
for FN patients accounted for 31% of total ﬁrst-line costs com-
pared to only 8% for N. Neutropenia-related costs during ﬁrst-
line were $2000 higher per month for FN when compared to N.
Costs unrelated to neutropenia were comparable between N and
FN when adjusted for variable follow-up. CONCLUSION: Neu-
tropenia, and in particular FN, add additional costs to ﬁrst-line
chemotherapy treatment in elderly advanced NSCLC patients.
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